Polymyositis Market Research Report 2026-2036: Competitive Landscape Is Dominated By Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, Abbvie, And Pfizer

(MENAFN- GlobeNewsWire - Nasdaq) The polymyositis market is witnessing notable growth driven by the increasing prevalence of this autoimmune disease, particularly among older adults. Polymyositis leads to muscle inflammation and weakness, highlighting the urgency for timely diagnosis and treatment. Advancements in therapeutics, especially in biologics and immunosuppressants, are enhancing treatment efficacy. Rising disease awareness and the demand for personalized treatments are fueling market expansion. Key growth regions include Asia-Pacific and Latin America, due to better healthcare infrastructure and telemedicine adoption. Major players like Teva, Gilead, and Pfizer are investing in innovative treatments. North America leads due to advanced infrastructure and research, with Asia-Pacific showing rapid growth.

Dublin, May 19, 2026 (GLOBE NEWSWIRE) -- The "Polymyositis Market - A Global and Regional Analysis: Focus on Treatment Type, Route of Administration, Country, 2026-2036" report has been added to ResearchAndMarkets's offering.
The polymyositis market is experiencing substantial growth due to an increasing global prevalence of the disease, particularly among older adults. Polymyositis is an autoimmune disorder that leads to inflammation and weakness in skeletal muscles, making early diagnosis and effective treatment crucial for patient outcomes.

The market is primarily driven by advancements in therapeutics, including the shift towards biologics and immunosuppressants, offering more targeted treatment options compared to traditional corticosteroids. Rising disease awareness, particularly among healthcare professionals and patients, is also driving demand for effective therapies. The need for personalized treatment options is creating opportunities for the development of drugs tailored to the specific genetic and clinical biomarker profiles of patients, which could significantly improve therapeutic efficacy.
Additionally, there is an increasing focus on emerging markets like Asia-Pacific and Latin America, where improving healthcare infrastructure and growing awareness of autoimmune disorders and drug delivery are expected to fuel market expansion. The integration of telemedicine platforms also represents a key opportunity, allowing for improved patient monitoring, accessibility to care, and better treatment adherence, especially in remote areas.

Regionally, North America holds the largest share of the market, attributed to its advanced healthcare infrastructure, substantial research investments, and higher disease awareness, while Europe also plays a critical role due to strong regulatory frameworks and ongoing collaborations in drug development. The Asia-Pacific region, with its large patient population and growing healthcare investments, is expected to show the fastest growth.

The competitive landscape is dominated by major players such as Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer, all of which are focusing on expanding their product pipelines through research and development to introduce innovative therapies. These companies are actively working to address the unmet needs in the polymyositis market, including the development of treatments that offer better safety profiles, improved efficacy, and convenient administration routes.

As the market continues to evolve, stakeholders who invest in novel drug development, regional market penetration, and digital health solutions will be well-positioned to capitalize on the growing demand for polymyositis treatments.

Global Polymyositis Market: Industry Outlook

• Market Overview and Ecosystem
• Polymyositis Disease Profile
• Treatment Landscape
• Clinical Presentation and Diagnosis
• Epidemiological Analysis of Polymyositis Market in U.S., EU5 and APAC Countries
• Regional Disease Incidence and Prevalence
• Distribution by Demographic Factors
• Geographical Distribution and Hotspots
• Age Distribution by Region
• Market Trends
• Clinical Trial Landscape
• Regulatory Landscape Analysis
• Legal Requirement and Framework in U.S.
• Legal Requirement and Framework in E.U.
• Legal Requirement and Framework in Asia-Pacific
• Legal Requirement and Framework in Rest-of-the-World
• Market Dynamics

Companies Featured

• Teva Pharmaceuticals
• Gilead Sciences
• Eli Lily and Company
• Celgene
• AsteraZeneca
• Amgen Inc.
• Bristol-Meyer Squibb
• AbbVie
• Pfizer, Inc.
• Boehringer Ingelheim.

Market Segmentation:

Treatment Type

• Corticosteroids
• Immunosuppressants
• Biologics
• Supportive therapies

ROA

• Oral
• Intravenous
• Intramuscular

Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19052026004107003653ID1111136795